Translating '–omics' results into precision medicine for hepatocellular carcinoma by Sia, Daniela & Llovet i Bayer, Josep Maria
Translating ‘–omics’ results into precision medicine for hepatocellular carcinoma 1 
Daniela Sia
1




(1) Mount Sinai Liver Cancer Program, The Tisch Cancer Institute, Icahn School of Medicine at 4 
Mount Sinai, 1425 Madison Avenue, New York 10029, USA  5 
(2) Liver Cancer Translational Research Laboratory, Liver Unit, Institut d’Investigacions 6 
Biomèdiques August Pi i Sunyer, Hospital Clínic, Univesitat de Barcelona, Rosselló 153, 7 
Barcelona 08039, Spain 8 
(3) Institució Catalana de Recerca i Estudis Avançats, Passeig de Lluís Companys 23, 9 
Barcelona 08010, Spain. 10 
Correspondence to J.M.L. Josep.Llovet@mssm.edu 11 
 12 
Acknowledgements 13 
J.M.P. is supported by grants from the US Department of Defense (CA150272P3) and Horizon 14 
2020 Program (HEPCAR, proposal number 667273–2), the Asociación Española Contra el 15 
Cáncer (AECC), Samuel Waxman Cancer Research Foundation, Spanish National Health 16 
Institute (SAF2016‑76390‑R) and Grup de Recerca Consolidat – Recerca Translacional en 17 
Oncologia Hepàtica. AGAUR (Generalitat de Catalunya), SGR 1162. 18 
 19 
Competing interests statement 20 
The authors declare no competing interests.  21 
Abstract 22 
A large-scale comprehensive analysis of hepatocellular carcinoma (HCC) based on the 23 
integration of six distinct data platforms has pinpointed novel oncogenic processes and 24 
prognostic subgroups. These findings confirm previously identified molecular subclasses and 25 
fuel the need for a clear strategy of precision medicine in HCC. 26 
Refers to Cancer Genome Atlas Research Network. Comprehensive and integrative genomic 27 
characterization of hepatocellular carcinoma. Cell 169, 1327–1341.e23 (2017). 28 
29 
The molecular landscape of HCC has changed dramatically over the past decade, aided by the 30 
advent of next-generation sequencing technologies that have uncovered the most frequently 31 
mutated oncogenic drivers (TERT promoter, TP53, CTNNB1), chromosomal aberrations (1q, 32 
8p, high-level gains of 11q13 and 6p21) and dysregulated signalling pathways (RAS– MAPK, 33 
Wnt, mechanistic target of rapamycin (mTOR), IGF2)1,2. After thoroughly analysing >1,000 34 
cases, the landscape of mutations and targetable drivers in HCC has been defined2. In 35 
addition, in an attempt to replicate the success obtained in proof‑of‑concept trials, such as 36 
crizotinib in ALK-rearranged lung cancers among others, great effort has been dedicated to the 37 
identification of subgroups of patients with specific molecular traits and tumour phenotypes2. 38 
Nonetheless, these advancements in the understanding of the molecular oncogenic drivers 39 
have not yet been translated into precision- medicine-driven trials1. In fact, effective targeted 40 
therapeutic options for patients with advanced HCC remain scarce and include the multityrosine 41 
kinase inhibitors sorafenib (first-line therapy)3, lenvatinib, just reported to be noninferior to 42 
sorafenib, and regorafenib (second-line therapy)4.  43 
In an effort to gain further insights into the underlying oncogenic processes and potential 44 
therapeutic targets, investigators from The Cancer Genome Atlas (TCGA) network have now 45 
taken the next step and performed large-scale molecular subtyping of HCC tumours, particularly 46 
in US patients5, thereby complementing previous efforts with European6 and Japanese 47 
patients7. Through the integrative analysis of DNA somatic mutations and copy number 48 
aberrations (n = 363 HCCs) with DNA methylation, proteomic, mRNA and microRNA expression 49 
profiling (n = 196), the highly powered analysis elegantly unveils novel potential oncogenic 50 
processes, such as metabolic reprogramming, and prognostic subgroups, such as those with 51 
isocitrate dehydrogenase 1 (IDH1), IDH2 and TP53 signatures5. Owing to the large sample 52 
size, the study not only confirms the most significantly mutated genes (TERT (44%), TP53 53 
(31%), CTNNB1 (27%), ARID1A (7%)) previously reported6,7, but also identifies low-rate 54 
mutations in eight novel candidate drivers (prevalence 1–4%), including genes altered in other 55 
cancers, such as LZTR1, EEF1A and SMARCA4 (REF. 5). Perhaps more interesting, the 56 
analysis suggests the existence of three prognostic molecular subgroups (termed iCluster1–3; 57 
FIG. 1). In particular, a TP53 signature associated with chromosomal instability and poor 58 
prognosis could further improve clinically relevant clustering of HCC, whereas IDH mutations in 59 
four tumours unveils a molecular subgroup with stem-cell-like features and close genomic 60 
similarity to cholangiocarcinoma5.  61 
Taken together, these data provide important insights into the genomic landscape of HCC and 62 
represent a notable comprehensive integrative genomic characterization of this neoplasm. 63 
Nonetheless, the clinical effect of such findings remains to be elucidated. The multiplatform 64 
clustering represents a solid confirmation of proposed molecular classifications, as the 65 
molecular traits and prognostic clusters show a high similarity to major subgroups previously 66 
reported (proliferation and nonproliferation)2, thereby further refining the paradigm of HCC 67 
molecular classification (FIG. 1). For example, the iCluster1 subgroup — characterized by high 68 
expression of proliferation marker genes and poor prognosis — highly resembles the previously 69 
reported proliferation subgroup2, whereas the characteristics of the iCluster2 subgroup 70 
(CTNNB1 mutations, less microvascular invasion) recall those of the nonproliferation class. 71 
Furthermore, except for mutations in TERT and CTNNB1, and promoter hypermethylation of 72 
CDKN2A, all pathway alterations seem evenly distributed among the three clusters, failing to 73 
provide sufficiently distinct multilevel molecular characterization and guide future treatment 74 
decision making. Similarly, the prognostic value of the distinct subgroups (iCluster1, IDH1/2, 75 
TP53) need to be further investigated, carrying out logistic regression analyses in fully 76 
annotated datasets and extensively validated.  77 
In terms of future therapeutic efforts, the authors highlight several potentially targetable drivers. 78 
This goal is certainly the major challenge, as we previously reported that HCC has few 79 
targetable drivers that account for less than one-third of patients with HCC, as opposed to 80 
cholangiocarcinoma, in which FGFR2 fusion proteins and IDH mutations are present in ~30% 81 
and 20% of patients, respectively1,2,6,8. In fact, most recurrently altered genes in HCC (TERT, 82 
TP53, CTNNB1) remain as unactionable targets, whereas the few targetable alterations occur 83 
only in a small fraction of patients (<10%)1. The first biomarker-driven clinical trials have 84 
recently emerged in HCC. For example, FGFR4 inhibitors are being tested (ClinicalTrials.gov; 85 
NCT02508467) in patients with high-level amplifications of chromosome 11q13 (FGF19), with 86 
more trials expected to follow1. In this regard, investigators of the TCGA network propose the 87 
use of MDM4 inhibitors in patients with wild-type TP53 and elevated MDM4 expression, or IDH 88 
inhibitors in patients with IDH1 or IDH2 mutations5. If this novel approach is confirmed in 89 
experimental studies, it can be added to the armamentarium of therapeutic strategies to be 90 
tested in early clinical trials.  91 
Activating mutations in IDH1 and/or IDH2 have been frequently reported (~20%) in intrahepatic 92 
cholangiocarcinoma and result in the acquisition of abnormal enzymatic activity that leads to 93 
altered cell differentiation and survival8. By contrast, IDH1 or IDH2 mutations have been rarely 94 
reported in HCC (<1%) and the data reported by TCGA (4 of 196 mutations; 2%) is in line with 95 
previous reports5–7. The relevance of these mutations towards HCC has been somewhat 96 
challenged because, as in the latest study, they always occurred in cholangiocarcinoma-like 97 
HCCs. Herein, the authors5 identify a subgroup of HCC (~10%) with an expression profile 98 
similar to the IDH-mutated HCCs that resemble the subgroup of mutant IDH1 or IDH2 99 
intrahepatic cholangiocarcinoma with stem-celllike features and poor prognosis signatures of 100 
HCC8. These findings further fuel the hypothesis that liver cancers might share a common 101 
progenitor precursor, at least in the subset of tumours with progenitor-like features and poor 102 
outcome8.  103 
As in other solid tumours, a new treatment paradigm is emerging. Recent results suggest that 104 
nivolumab, a monoclonal antibody against programmed cell death protein 1 (PD1) that 105 
modulates the immune system, produces durable responses in advanced HCCs (objective 106 
response rate of 20% and median survival of 16 months)9. However, clinical benefit is not 107 
related to PDL1 (the PD1 ligand) status on tumour cells9, highlighting the need to identify 108 
alternative biomarkers to select ideal candidates for immunotherapy. To this end, the 109 
observation by TCGA investigators that 22% of patients with HCC display high or moderate 110 
levels of lymphocyte infiltration is of great interest5. This discovery is consistent with data 111 
recently reported by our group defining the ‘immune class’ of tumours in ~27% of patients with 112 
HCC, which is characterized by high infiltration of immune cells, expression of PD1 and PDL1, 113 
and active IFNγ signalling10. Further investigation of the antitumour immune responses and the 114 
interplay between cancer cells and the microenvironment will be critical for understanding if this 115 
subgroup of patients might benefit from these therapies. In conclusion, genomics have 116 
improved the understanding of the biology of HCC, but this knowledge has not yet been 117 
translated into clinical practice. This study further fuels the concept that investigators are 118 
striding down the right path towards precison medicine in HCC.   119 
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Figure 1. Molecular classification of HCC. The figure shows the overlap between 3 iClusters 
identified from the analysis conducted by the The Cancer Genome Atlas (TCGA) Network (a)5 
and the two major clusters previously proposed by Zucman-Rossi et al. (b)2. Bold text indicates 
common characteristics between the clusters of both proposals. See Zucman-Rossi et al.2 for 
details on subclasses termed S1–S3 and Cluster A or B. AFP, α-fetoprotein. 
 
A) iCluster1 iCluster2 iCluster3 
Clinical features • Asian ethnicity 
• High-grade tumours 
• Macrovascular invasion 
• Worse outcome 
 • Low-grade tumours 
• Less microvascular 
invasion 
• Better outcome 
DNA somatic 
alterations 
• BAP1 mutations • High chromosome 
instability 
• Chromosome17p loss 
• CDKN2A 
hypermethylation 





• IDH1/2 signature 
• S2 subtype 
 • CDKN2A 
hypermethylation 
• TERT mutations 
• CTNNB1 mutations 
B) Proliferation Non-Proliferation 
 Progenitor-like Hepatocyte-like Hepatocyte-like 
Clinical features • HBV 
• High AFP 
• Poor differentiation 
• Vascular invasion 
• Worse outcome 
 • HCV 
• Low AFP 
• Well–moderate 
differentiation 
• Less vascular invasion 
• Better outcome 
DNA somatic 
alterations 
• Chromosome 11q13 
amplification (FGF19) 
• Poor differentiation 
• Vascular invasion 
• Worse outcome 




• S2 subtype 
• Hepatoblastoma C2 
• Hepatoblast-like 
• Cluster A 
• Vascular invasion 
• Late TGFβ 
• S1 subtype 
• Cluster A 
• S3 subtype 
• Cluster B 
 
